Research on metastatic melanoma patients undergoing anti-PD-1 therapy identified a higher IFN-γ/IL-10 ratio in responders, suggesting its potential as a predictive tool for therapeutic outcomes [30]. This evidence concerns the gene IFNG and metastatic melanoma.